Cosmetic Regional Conjunctivectomy With Postoperative Mitomycin C Application With or Without Bevacizumab?Injection

详细信息    查看全文

• 作者：Seonheui Lee ; Jeongae Go ; Soolienah Rhiu ; R. Doyle Stulting ; Min Lee ; Sunyoung Jang ; Sangmoo Lee ; Hyung Joon Kim ; Eui Sang Chung ; Sooyoung Kim ; Kyoung Yul Seo
• 刊名：American Journal of Ophthalmology
• 出版年：2013
• 出版时间：September, 2013
• 年：2013
• 卷：156
• 期：3
• 页码：616-622.e3
• 全文大小：1034 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Purpose

To evaluate the complications of cosmetic wide conjunctivectomy and postoperative topical mitomycin C application with or without bevacizumab injection.

Design

Cross-sectional cohort study.

Methods

Medical records of 1713 consecutive subjects who received cosmetic wide conjunctivectomy plus postoperative topical mitomycin C by a single surgeon at a single center with or without bevacizumab injection from November 2007 to May 2010 were reviewed. A telephone interview was conducted with 557 of the subjects who could be contacted and agreed to participate in the study. Complications, recurrences, and patient satisfaction were the main outcome measures.

Results

A total of 1713 consecutive patients underwent cosmetic wide conjunctivectomy to treat conjunctival hyperemia. Ocular diagnoses in the medical records at the time of surgery included hyperemia (8.8 % ), pterygium (14.0 % ), dry eye (3.5 % ), pinguecula (1.5 % ), and conjunctival disorder (23.3 % ). For the remaining 48.9 % of subjects, the diagnosis was not mentioned, or the surgical procedure was for cosmetic purposes. Patients were followed for a mean of 10.9?months (range, 0-30.3?months). The overall complication rate was 82.9 % , of which 55.6 % were considered severe (fibrovascular conjunctival tissue proliferation, 43.8 % ; scleral thinning, 4.4 % ; scleral thinning with calcified plaques, 6.2 % ; intraocular pressure elevation, 13.1 % ; diplopia, 3.6 % ; and recurrence of hyperemic conjunctiva, 28.1 % ).

Conclusions

Cosmetic wide conjunctivectomy plus postoperative topical mitomycin C with or without bevacizumab injection has a high rate of complications and reoperations.